Hester Biosciences Limited (BSE: 524669)
Health Care · Biotechnology · IN
Rs2,385.90
-1.15% today · +12.0% 1Y
Hester Biosciences Limited (BSE: 524669) operates in the Biotechnology industry within the Health Care sector. The company is valued at $212.13M.
Over the last twelve months the share price has gained 12.0%, trading between 1.25K and 2.67K.
Tweenvest scores Hester Biosciences Limited across four factors: quality 76/100, value 53/100, growth 68/100, dividend 67/100. Its strongest factor is quality.
524669 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $212.13M
- Revenue (TTM)
- $34.61M
- P/E
- 15.10
- EPS
- 158.03
- Dividend yield
- 0.46%
- Beta (5Y)
- 0.43
- 52-week high
- Rs2,669.00
- 52-week low
- Rs1,250.95
- Avg volume (3M)
- —
- Shares outstanding
- 8.51M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.77 | +2.07% |
Figures last refreshed Aug 18, 2026.